Anti-Cancer Agents in Medicinal Chemistry
Title: Editorial [Hot Topic: Nanomedicine for Cancer (Guest Editor: Vladimir P. Torchilin)]
Volume: 6 Issue: 6
Author(s): Vladimir P. Torchilin
Affiliation:
Export Options
About this article
Cite this article as:
Torchilin P. Vladimir, Editorial [Hot Topic: Nanomedicine for Cancer (Guest Editor: Vladimir P. Torchilin)], Anti-Cancer Agents in Medicinal Chemistry 2006; 6 (6) . https://dx.doi.org/10.2174/187152006778699103
DOI https://dx.doi.org/10.2174/187152006778699103 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
21
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Emerging Role of Endoglin (CD105) as a Marker of Angiogenesis with Clinical Potential in Human Malignancies
Current Cancer Drug Targets The Role of Adipokines in the Establishment and Progression of Head and Neck Neoplasms
Current Medicinal Chemistry Chaperonopathies and Chaperonotherapy. Hsp60 as Therapeutic Target in Cancer: Potential Benefits and Risks
Current Pharmaceutical Design Choice of Biologic Therapy for Patients with Rheumatoid Arthritis: The Infection Perspective
Current Rheumatology Reviews Mining the Genome for Susceptibility to Complex Neurological Disorders
Current Molecular Medicine Tissue Transglutaminase Expression During Neural Differentiation of Human Mesenchymal Stem Cells
CNS & Neurological Disorders - Drug Targets Cellular Redox Modulator, ortho Mn(III) meso-tetrakis(N-n-Hexylpyridinium-2-yl)porphyrin, MnTnHex-2-PyP5+ in the Treatment of Brain Tumors
Anti-Cancer Agents in Medicinal Chemistry Editorial (Thematic Issue: Lutetium-177 Labeled Therapeutics: 177Lu-PSMA is Set to Redefine Prostate Cancer Treatment)
Current Radiopharmaceuticals The Economics of Pharmacogenomics
Current Pharmacogenomics Circulating Tumor Stem Cells as Biomarkers for Cancer Progression
Recent Patents on Biomarkers Factors Driving the Choice of the Best Second-Line Treatment of Advanced NSCLC
Reviews on Recent Clinical Trials Heterocyclization of Thiophenes Derived from Estrone Followed by Cytotoxic, HTRF Kinase and Pim-1 Kinase Evaluations
Anti-Cancer Agents in Medicinal Chemistry Oxaliplatin Based Chemotherapy and Concomitant Highly Active Antiretroviral Therapy in the Treatment of 24 Patients with Colorectal Cancer and HIV Infection
Current HIV Research Endoplasmic Reticulum Stress, Calcium Dysregulation and Altered Protein Translation: Intersection of Processes That Contribute to Cancer Cachexia Induced Skeletal Muscle Wasting
Current Drug Targets Update on the Principles and Novel Local and Systemic Therapies for the Treatment of Non-Infectious Uveitis
Inflammation & Allergy - Drug Targets (Discontinued) Prediction of Late Recurrence and Distant Metastasis in Early-stage Breast Cancer: Overview of Current and Emerging Biomarkers
Current Drug Targets The Promise and Obstacle of p53 as a Cancer Therapeutic Agent
Current Molecular Medicine Fluorescent Substrates Useful as High Throughput Screening Tools for ADAM9
Combinatorial Chemistry & High Throughput Screening Synthesis and Evaluation of 2-Naphthaleno trans-Stilbenes and Cyanostilbenes as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry The Chemistry and Pharmacology of Genistein
The Natural Products Journal